Evidence map›Paper›PMID 39257578›Full record

ArticleFrontiers in immunology2024

Enhanced and cross-reactive

Zoe Marti, Josefine Ruder, Olivia G Thomas, Mattias Bronge, Lorenzo De La Parra Soto, Hans Grönlund, Tomas Olsson, Roland Martin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zoe MartiInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Josefine RuderDepartment of Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich, Zurich, Switzerland.
Olivia G ThomasTherapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Mattias BrongeTherapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lorenzo De La Parra SotoTherapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Hans GrönlundTherapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Tomas OlssonNeuroimmunology Unit, Department of Clinical Neurocience, Karolinska Institutet, Stockholm, Sweden.
Roland MartinInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a prototypical autoimmune disease of the central nervous system (CNS). In addition to CD4

Indexed as

Cross ReactionsEpstein-Barr Virus Nuclear AntigensMemory B CellsMultiple SclerosisAdultAntibodies, ViralB-LymphocytesEpstein-Barr Virus InfectionsFemaleHerpesvirus 4, HumanHumansImmunologic MemoryMaleMiddle AgedAntibodies, ViralEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear Antigensanoctamin-2EBNA1Epstein-Barr virusGlialCAMmemory B cellsmolecular mimicrymultiple sclerosisnatalizumab

Identifiers

PMID39257578
PMCPMC11385009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.